Under the EU MDR 2017/745, risk management is no longer a static document generated during the R&D phase and filed away. It is a continuous, iterative lifecycle process. For Regulatory Affairs and Quality Managers, establishing a robust mdr risk management framework is the critical foundation that directly dictates the success of your Clinical Evaluation, Post-Market Surveillance (PMS), and overall Technical Documentation.
To demonstrate compliance with the General Safety and Performance Requirements (GSPRs) of Annex I, manufacturers must deeply integrate ISO 14971:2019 methodologies into their Quality Management System (QMS), ensuring that risks are reduced "As Far As Possible" (AFAP).
The Standard: ISO 14971:2019 and EU MDR Alignment
While iso 14971 eu mdr compliance is technically achieved through a "voluntary" standard, Notified Bodies treat EN ISO 14971:2019+A11:2021 as the absolute baseline. The 'Z-Annexes' of the European harmonized version explicitly map the clauses of the standard to the GSPRs of the MDR.
A major shift introduced by the MDR is the outright rejection of the ALARP (As Low As Reasonably Practicable) concept in favor of AFAP. Under the MDR, economic or financial considerations can no longer be used to justify accepting a higher level of risk if a further reduction is technically feasible.
Building the Risk Management Plan (RMP)
The risk management plan medical device is your blueprint. It defines the scope of the risk activities, assigns responsibilities, and most importantly, establishes the criteria for risk acceptability. Your plan must include:
- Scope of the device: Intended purpose, user profile, and clinical environment.
- Lifecycle phases: Defining risk activities from initial design through to decommissioning.
- Acceptability criteria: Clear, objective metrics to evaluate whether residual risks are acceptable compared to the clinical benefits.
- Post-market triggers: How PMS and PMCF data will trigger a review and potential update of the risk analysis.
Performing the Risk Analysis & Evaluation
The risk analysis medical device eu mdr requires identifying all potential hazards (e.g., biological, environmental, functional) and foreseeable sequences of events that could lead to a hazardous situation. Risks are estimated by combining the probability of occurrence of harm and the severity of that harm.
| Risk Process Phase | MDR Expectation |
|---|---|
| Hazard Identification | Must include normal use, foreseeable misuse, and usability engineering (IEC 62366-1) considerations. |
| Risk Control (AFAP) | Must prioritize inherent safety by design, then protective measures (alarms), then information for safety (IFU/training). Warnings alone are no longer sufficient to lower the actual risk level. |
| Residual Risk Evaluation | Overall residual risk must be evaluated against the clinical benefit documented in the CER. It must be deemed acceptable. |
The Golden Triangle: Risk Management, CER, and PMCF
A frequent source of Notified Body major non-conformities is the misalignment between the Risk Management File (RMF), the Clinical Evaluation, and Post-Market activities. These three documents must "speak the same language."
Strategic Alignment
Your risk framework cannot exist in a silo. It feeds, and is fed by, two critical MDR pillars:
1. Clinical Evaluation Report (CER)
The CER must directly address the clinical risks identified in your risk analysis. If a side effect is listed in the risk file, the CER must provide clinical data proving that the benefit outweighs this specific risk.
Read the Complete CER Guide →2. Post-Market Clinical Follow-up (PMCF)
If your risk evaluation relies on assumptions about long-term durability or rare complications, PMCF is how you validate those assumptions in the real world. PMCF data continuously flows back to update the risk file.
Read the PMCF CRO Guide →The Risk Management File (RMF) and Report
The output of this entire process is the Risk Management File, which culminates in the Risk Management Report. This report summarizes the process, confirms that the risk plan was appropriately executed, and provides the final sign-off that the overall residual risk is acceptable. During an audit, this file must be readily accessible, impeccably version-controlled, and clearly linked to the Technical Documentation.